ChiCTR2600127215 版本V1.0 版本创建时间2026/06/26 15:56:36 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600127215 

最近更新日期:

Date of Last Refreshed on:

2026-06-26 15:56:16 

注册时间:

Date of Registration:

2026-06-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于经直肠双平面超声的子宫脱垂宫颈长度精准测量与顶端支持结构影像化评估研究

Public title:

Study on Precise Measurement of Cervical Length and Imaging Evaluation of Apical Support Structures for Uterine Prolapse Based on Transrectal Biplane Ultrasound

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于经直肠双平面超声的子宫脱垂宫颈长度精准测量与顶端支持结构影像化评估研究

Scientific title:

Study on Precise Measurement of Cervical Length and Imaging Evaluation of Apical Support Structures for Uterine Prolapse Based on Transrectal Biplane Ultrasound

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王玥 

研究负责人:

王玥 

Applicant:

Wang Yue 

Study leader:

Wang Yue 

申请注册联系人电话:

Applicant telephone:

+86 755 83923333

研究负责人电话:

Study leader's
telephone:

+86 755 83923333

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sonoview@163.com

研究负责人电子邮件:

Study leader's E-mail:

sonoview@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市福田区莲花路1120号

研究负责人通讯地址:

广东省深圳市福田区莲花路1120号

Applicant address:

No. 1120, Lianhua Road, Futian District, Shenzhen,Guangdong

Study leader's address:

No. 1120, Lianhua Road, Futian District, Shenzhen,Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学深圳医院

Applicant's institution:

Peking University Shenzhen Hospital

研究负责人所在单位:

北京大学深圳医院

Affiliation of the Leader:

Peking University Shenzhen Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

北大深医伦审(研)[2026]第(154)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学深圳医院科研伦理审查委员会

Name of the ethic committee:

Research Ethics Review Committee of Peking University Shenzhen Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-28 00:00:00

伦理委员会联系人:

杨珍妮

Contact Name of the ethic committee:

Jenny

伦理委员会联系地址:

广东省深圳市福田区莲花路1120号

Contact Address of the ethic committee:

No. 1120, Lianhua Road, Futian District, Shenzhen,Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 83923333

伦理委员会联系人邮箱:

Contact email of the ethic committee:

3125392358@qq.com

研究实施负责(组长)单位:

北京大学深圳医院

Primary sponsor:

Peking University Shenzhen Hospital

研究实施负责(组长)单位地址:

广东省深圳市福田区莲花路1120号

Primary sponsor's address:

No. 1120, Lianhua Road, Futian District, Shenzhen,Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

北京大学深圳医院

具体地址:

广东省深圳市福田区莲花路1120号

Institution
hospital:

Peking University Shenzhen Hospital

Address:

No. 1120, Lianhua Road, Futian District, Shenzhen,Guangdong

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Optional topic (self raised)

研究疾病:

子宫脱垂(Uterine Prolapse, UP)  

Target disease:

Uterine Prolapse (UP)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

建立经直肠双平面超声对子宫脱垂相关宫颈长度及POP-Q顶端关键点的标准化影像学测量方法,以等效性评价为核心,验证其与手术-病理复合参照标准及临床POP-Q评分的一致性,形成可重复、可质控的POP顶端支持结构影像化评估体系。  

Objectives of Study:

To establish a standardized imaging measurement method for cervical length and apical key points of POP-Q in uterine prolapse using transrectal biplane ultrasound. Centered on equivalence evaluation, this study verifies its consistency with the combined surgical-pathological reference standard and clinical POP-Q scoring, and develops a reproducible and quality-controllable imaging evaluation system for pelvic apical support structures of pelvic organ prolapse (POP).

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18岁女性;
2.临床诊断或疑似盆腔器官脱垂,POP-Q分期≥I期;
3.可配合完成临床POP-Q评分;
4.可耐受经直肠双平面超声检查;
5.可完成有效Valsalva动作;
6.临床资料完整;
7.理解并自愿签署书面知情同意书;
8.纳入宫颈长度准确性验证队列者,需拟接受子宫切除术或宫颈截除术,并可获得手术及病理参照测量;

Inclusion criteria

1.Women aged >= 18 years; 2.Clinically diagnosed or suspected POP, POP-Q stage >= I; 3.Able to complete clinical POP-Q assessment cooperatively; 4.Able to tolerate transrectal biplane ultrasonography; 5.Able to perform effective Valsalva maneuver; 6.With complete clinical data available; 7.Fully understood the study and voluntarily provided written informed consent; 8.Participants enrolled in the cervical length accuracy verification cohort are scheduled to undergo hysterectomy or trachelectomy, with surgical and pathological reference measurements available;

排除标准:

1.既往全子宫切除术后且无法评价宫颈相关指标者;
2.盆腔恶性肿瘤或疑似恶性肿瘤者;
3.严重生殖道畸形影响宫颈或阴道结构定位者;
4.近6个月内接受盆底重建术者;
5.急性阴道、宫颈、盆腔或直肠感染者;
6.严重肛直肠疾病不能接受经直肠检查者;
7.既往盆腔放疗史;
8.不能完成有效Valsalva动作;
9.图像质量无法满足关键结构识别;
10.妊娠期或产后6个月内女性;
11.BMI≥35 kg/m2者不直接排除,但单独标记并进行亚组或敏感性分析;

Exclusion criteria:

1.Patients with prior total hysterectomy and unavailable cervical-related indicators; 2.Patients with pelvic malignant tumors or suspected malignancy; 3.Patients with severe genital tract malformations interfering with localization of cervical or vaginal structures; 4.Patients who underwent pelvic floor reconstruction within the past 6 months; 5.Patients with acute infection of the vagina, cervix, pelvis or rectum; 6.Patients with severe anorectal diseases who cannot undergo transrectal examination; 7.Prior history of pelvic radiotherapy; 8.Unable to perform effective Valsalva maneuver; 9.Image quality inadequate for identification of key structures; 10.Pregnant females or those within 6 months postpartum; 11.Participants with BMI >= 35 kg/m^2 will not be directly excluded, but will be separately labeled for subgroup and sensitivity analyses.

研究实施时间:

Study execute time:

From 2026-06-29 00:00:00 To 2029-06-28 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-29 00:00:00 To 2028-03-28 00:00:00

干预措施:

Interventions:

组别:

宫颈长度准确性验证队列

样本量:

80

Group:

Cervical length accuracy verification cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

POP-Q关键点可视化队列

样本量:

165

Group:

POP-Q landmark visualization cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

北京大学深圳医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University Shenzhen Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

宫颈曲线追踪长度

指标类型:

主要指标

Outcome:

Curvilinear cervical length

Type:

Primary indicator

测量时间点:

超声检查与临床POP-Q评分原则上同日完成,特殊情况下间隔不超过7天。绝经前患者尽量安排在月经周期第5–10天检查。

测量方法:

在经直肠双平面超声矢状面或最佳显示切面上,曲线追踪测量宫颈内口至宫颈外口的距离

Measure time point of outcome:

Ultrasound examination and clinical POP-Q assessment shall be completed on the same day in principle

Measure method:

On the sagittal plane or optimal view of transrectal biplane ultrasound, measure the distance from the internal cervical os to the external cervical os via curvilinear tracing.

指标中文名:

宫颈直线长度

指标类型:

次要指标

Outcome:

Straight-line cervical length

Type:

Secondary indicator

测量时间点:

测量方法:

在经直肠双平面超声矢状面或最佳显示切面上,测量宫颈内口至宫颈外口的直线距离

Measure time point of outcome:

Measure method:

On the sagittal plane or optimal view of transrectal biplane ultrasound, measure the linear distance from the internal cervical os to the external cervical os.

指标中文名:

POP-Q关键点

指标类型:

次要指标

Outcome:

POP-Q landmarks

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

宫颈

组织:

Sample Name:

Cervix

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No raw date will be shared.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF 表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-26 15:56:16